Sentinel node biopsy in head and neck cancer: development of a new technique

Sentimag and MRI interstitial lymphangiography in Head and Neck cancer Sentinel Node Biopsy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN44750045

Enrollment

Registered

2019-02-06

Start date

2014-01-07

Completion date

Unknown

Last updated

2019-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Head and Neck cancer Cancer

Interventions

The intervention involves injecting a small iron oxide nanoparticles around the tumor. Then, the patient is taken to theater to undergo tumor resection and a neck dissection. Before doing the neck dis

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Diagnosed with a new cN0 HNSCC within the oral cavity and oropharynx 2. Multi-disciplinary tumor board proposal is surgical treatment.

Exclusion criteria

Exclusion criteria: 1. Age below 18 years old at the time of diagnosis 2. Pregnancy 3. Previous Head and Neck cancer 4. Other cancer in the last two years (other than non-melanoma skin cancer) 5. Previous neck radiotherapy 6. Contra-indication to magnetic resonance Imaging (pacemeaker, cerebral metallic implant, claustrophobia) 7. Overload iron disease 8. Allergy to dextran

Design outcomes

Primary

Measure	Time frame
Correlation of nodal staging with Sentimag® guided SLNB and the nodal staging by the completion neck dissection .	—

Secondary

Measure	Time frame
1. Identification of the SPION tracer in the SLN with pre-operative T2* MRI 2. Per-operative identification of the SLN with Sentimag®-guidance 3. Histopathological detection of the SPION in the SLN and in the remaining nodes within the completion neck dissection.	—

Countries

Switzerland

Contacts

Public ContactNicolas Dulguerov

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026